该行表示，考虑到2023年公司完成辽健和江能集团收购，该行将公司2024-2026年营业收入上调为105.20、110.84、117.46亿元，同比增长分别为4.08%、5.37%、5.97%；归属于上市公司股东的净利润分别为7.44、7.82、8.17亿元，同比增长分别为188.90%、5.02%、4.50%。公司市场规模领先并具有良好的增长潜力，维持“买入”评级。Jingu Financial News | Tianfeng Securities issued a research report, stating that cr medical (01515) achieved revenue of 4.976 billion yuan in H1 2024, a decrease of 2.7% year-on-year, and a net income of 0.434 billion yuan, an increase of 9.0% year-on-year, with overall performance meeting expectations.
The bank pointed out that in H1 2024, both outpatient and inpatient visits of self-owned hospitals achieved growth, with approximately 5.05 million and 280,000 visits respectively, representing a 3.5% and 3.0% increase from the same period last year; due to the impact of two-year medical insurance settlement differences, both outpatient and inpatient revenues declined, with decreases of 2.0% and 8.8% respectively.
The bank further mentioned that cr medical is the main platform for CR Group's layout in the medical health field and has become a leading state-owned comprehensive medical group. With the completion of asset mergers and integration, continuous deepening of integrated fine management, and gradual elimination of non-recurring influences, the company's business scale and profitability are expected to continuously improve.
The bank stated that considering the completion of the Liaojian and Jiangneng Group acquisitions in 2023, the bank has raised the company's revenue for 2024-2026 to 10.52, 11.084, 11.746 billion yuan, with year-on-year growth of 4.08%, 5.37%, 5.97% respectively; the net income attributable to shareholders of the listed company is expected to be 0.744, 0.782, 0.817 billion yuan, with year-on-year growth of 188.90%, 5.02%, 4.50% respectively. The company leads the market in size and has good growth potential, maintaining a 'buy' rating.
